3-氯-5-硝基水杨酸 | 349586-65-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯-5-硝基水杨酸
• 英文名称: 3-chloro-5-nitrosalicylic acid
• 英文别名: 3-chloro-2-hydroxy-5-nitro-benzoic acid；3-Chlor-2-hydroxy-5-nitro-benzoesaeure；3-Chlor-5-nitro-salicylsaeure；3-Chloro-2-hydroxy-5-nitrobenzoic acid
• CAS: 349586-65-8
• 化学式: C₇H₄ClNO₅
• 分子量: 217.565
• InChiKey: NKALRCUMHHXJRN-UHFFFAOYSA-N

物化性质

• 熔点：
  202-203 °C
• 沸点：
  376.5±42.0 °C(Predicted)
• 密度：
  1.751±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-氯-5-硝基水杨酸 在 palladium on activated charcoal 、 氢气 作用下， 以 乙醇 为溶剂， 生成 5-amino-3-chloro-2-hydroxy-benzoic acid
  参考文献：
  名称：

  苯并噻唑尿素是17β-HSD10的低微摩尔和非竞争性抑制剂，与阿尔茨海默氏病的治疗有关

  摘要：

  人17β-羟类固醇脱氢酶10型是一种多功能蛋白，参与线粒体内的许多酶和结构过程。该酶被认为与几种神经系统疾病有关，例如智力低下，帕金森氏病或阿尔茨海默氏病，其中该酶与淀粉样β肽相互作用。我们基于苯并噻唑基支架制备了约60种新化合物，并评估了它们的抑制能力和作用机理。最有效的抑制剂在苯环部分包含3-氯和4-羟基取代基，在苯并噻唑部分的6位上具有小的取代基，并且两个部分通过脲连接基连接（4at，4bb和4bg）。这些化合物的IC50值为1-2μM，对底物乙酰乙酰辅酶A表现出无竞争性的作用机理。这些17β-羟基类固醇脱氢酶的非竞争性苯并噻唑基抑制剂是有希望用于神经退行性疾病潜在药物的化合物，值得进一步研究和开发。

  DOI：

  10.3390/ijms21062059
• 作为产物：
  描述：

  3 -氯- 2 -羟基苯 在 sodium hydroxide 、 potassium dicarbonate 、 硝酸 、 permanganate(VII) ion 、 溶剂黄146 、 silver(l) oxide 作用下， 生成 3-氯-5-硝基水杨酸
  参考文献：
  名称：

  Davies; Rubenstein, Journal of the Chemical Society, 1923, vol. 123, p. 2850

  摘要：

  DOI：

文献信息

• The use of substituted carbocyclic compounds as rotamases inhibitors
  申请人：Jerini AG

  公开号：EP1402888A1

  公开（公告）日：2004-03-31

  The present invention is related to the use of a compound as an inhibitor to a rotamase, whereby the compound has the structure:         A-X-Y     (I) wherein A is cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl; X is a spacer and is selected from X1 or X2, wherein X1 is selected from the group comprising -[(CRaRb)n-NRc-CO-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-CS-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-C(N-CN)-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-C(N-Re)-NRd-(CRaRb)m]t-, -[(CRaRb)n-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-CO-O-(CRaRb)m]t-, -[(CRaRb)n-O-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-O-(CRaRb)m]t-, -[(CRaRb)n-SRc-(CRaRb)m]t-; wherein X2 is selected from the group comprising - [(CRaRb)n-CO-(CRaRb)m]t-, -[(CRaRb)n-CS-(CRaRb)m]t-, -[(CRaRb)n-NRc-CO-(CRaRb)m]t-, -[(CRaRb)n-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-CS-(CRaRb)m]t-, -[(CRaRb)n-CS-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-SO2-(CRaRb)m]t-, -[(CRaRb)n-SO2-NRc-(CRaRb)m]t-, -[(CRaRb)n-SO-(CRaRb)m]t-, -[(CRaRb)n-SO2-(CRaRb)m]t-, -[(CRaRb)n]t-; wherein n and m are independently selected from each other and are any integer between 0 and 10 provided that if n is 0, m is different from 0, and if m is 0, n is different from 0; wherein t is independently selected from n and/or m and is any integer between 0 and 10; wherein Ra, Rb, Rc, Rd and Re are independently from each other selected from the group comprising H, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein Y is selected from the group comprising alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide.

  本发明涉及将某种化合物作为旋转酶的抑制剂使用，其中该化合物具有以下结构：        A-X-Y     (I)其中A为环烷基、取代环烷基、杂环烷基、取代杂环烷基、芳基、取代芳基、杂芳基或取代杂芳基；X为间隔物，可从X1或X2中选择，其中X1可从以下组中选择：-[(CRaRb)n-NRc-CO-NRd-(CRaRb)m]t-，-[(CRaRb)n-NRc-CS-NRd-(CRaRb)m]t-，-[(CRaRb)n-NRc-C(N-CN)-NRd-(CRaRb)m]t-，-[(CRaRb)n-NRc-C(N-Re)-NRd-(CRaRb)m]t-，-[(CRaRb)n-CO-NRc-(CRaRb)m]t-，-[(CRaRb)n-NRc-(CRaRb)m]t-，-[(CRaRb)n-NRc-CO-O-(CRaRb)m]t-，-[(CRaRb)n-O-CO-NRc-(CRaRb)m]t-，-[(CRaRb)n-O-(CRaRb)m]t-，-[(CRaRb)n-SRc-(CRaRb)m]t-；其中X2可从以下组中选择：-[(CRaRb)n-CO-(CRaRb)m]t-，-[(CRaRb)n-CS-(CRaRb)m]t-，-[(CRaRb)n-NRc-CO-(CRaRb)m]t-，-[(CRaRb)n-CO-NRc-(CRaRb)m]t-，-[(CRaRb)n-NRc-CS-(CRaRb)m]t-，-[(CRaRb)n-CS-NRc-(CRaRb)m]t-，-[(CRaRb)n-NRc-SO2-(CRaRb)m]t-，-[(CRaRb)n-SO2-NRc-(CRaRb)m]t-，-[(CRaRb)n-SO-(CRaRb)m]t-，-[(CRaRb)n-SO2-(CRaRb)m]t-，-[(CRaRb)n]t-；其中n和m相互独立选择，为0到10之间的任意整数，条件是如果n为0，则m与0不同，如果m为0，则n与0不同；其中t从n和/或m中独立选择，为0到10之间的任意整数；其中Ra、Rb、Rc、Rd和Re相互独立选择，可从H、烷基、环烷基、芳基、杂芳基和杂环烷基中选择；Y可从烷基、取代烷基、环烷基、取代环烷基、环烯基、取代环烯基、杂环烷基、取代杂环烷基、单不饱和杂环烷基、多不饱和杂环烷基、单取代多不饱和杂环烷基、多取代多不饱和杂环烷基、芳基、取代芳基、杂芳基和取代杂芳基中选择，其中Y与肽不同。
• New compounds for the inhibition of undesired cell proliferation and use thereof
  申请人：Jerini AG

  公开号：EP1402887A1

  公开（公告）日：2004-03-31

  The present invention is related to the use of a compound for the manufacture of a medicament for the treatment of a disease, whereby the disease involves an abnormal cell proliferation, an undesired cell proliferation, an abnormal mitosis and/or an undesired mitosis. whereby the compound has the structure:         A-X-Y     (I) wherein A is cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl; X is a spacer and is selected from X1 or X2, wherein X1 is selected from the group comprising -[(CRaRb)n-NRc-CO-NRd-(CRaRb)m]t-, [(CRaRb)n-NRc-CS-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-C(N-CN)-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-C(N-Re)-NRd-(CRaRb)m]t-, -[(CRaRb)n-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-CO-O-(CRaRb)m]t-, -[(CRaRb)n-O-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-O-(CRaRb)m]t-, -[(CRaRb)n-SRc-(CRaRb)m]t-; wherein X2 is selected from the group comprising -[(CRaRb)n-CO-(CRaRb)m]t-, -[(CRaRb)n-CS-(CRaRb)m]t-, -[(CRaRb)n-NRc-CO-(CRaRb)m]t-, -[(CRaRb)n-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-CS-(CRaRb)m]t-, -[(CRaRb)n-CS-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-SO2-(CRaRb)m]t-, -[(CRaRb)n-SO2-NRc-(CRaRb)m]t-, -[(CRaRb)n-SO-(CRaRb)m]t-, -[(CRaRb)n-SO2-(CRaRb)m]t-, -[(CRaRb)n]t-; wherein n and m are independently selected from each other and are any integer between 0 and 10 provided that if n is 0, m is different from 0, and if m is 0, n is different from 0; wherein t is independently selected from n and/or m and is any integer between 0 and 10; wherein Ra, Rb, Rc, Rd and Re are independently from each other selected from the group comprising H, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein Y is selected from the group comprising alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide.

  本发明涉及一种化合物用于制造治疗疾病的药物，其中该疾病涉及异常细胞增殖、不良细胞增殖、异常有丝分裂和/或不良有丝分裂，其中该化合物具有以下结构：A-X-Y（I），其中A为环烷基、取代环烷基、杂环烷基、取代杂环烷基、芳香族、取代芳香族、杂芳香族或取代杂芳香族；X为间隔物，选择自X1或X2，其中X1选择自包括-[(CRaRb)n-NRc-CO-NRd-(CRaRb)m]t-、[(CRaRb)n-NRc-CS-NRd-(CRaRb)m]t-、-[(CRaRb)n-NRc-C(N-CN)-NRd-(CRaRb)m]t-、-[(CRaRb)n-NRc-C(N-Re)-NRd-(CRaRb)m]t-、-[(CRaRb)n-CO-NRc-(CRaRb)m]t-、-[(CRaRb)n-NRc-(CRaRb)m]t-、-[(CRaRb)n-NRc-CO-O-(CRaRb)m]t-、-[(CRaRb)n-O-CO-NRc-(CRaRb)m]t-、-[(CRaRb)n-O-(CRaRb)m]t-、-[(CRaRb)n-SRc-(CRaRb)m]t-；其中X2选择自包括-[(CRaRb)n-CO-(CRaRb)m]t-、-[(CRaRb)n-CS-(CRaRb)m]t-、-[(CRaRb)n-NRc-CO-(CRaRb)m]t-、-[(CRaRb)n-CO-NRc-(CRaRb)m]t-、-[(CRaRb)n-NRc-CS-(CRaRb)m]t-、-[(CRaRb)n-CS-NRc-(CRaRb)m]t-、-[(CRaRb)n-NRc-SO2-(CRaRb)m]t-、-[(CRaRb)n-SO2-NRc-(CRaRb)m]t-、-[(CRaRb)n-SO-(CRaRb)m]t-、-[(CRaRb)n-SO2-(CRaRb)m]t-、-[(CRaRb)n]t-；其中n和m彼此独立选择且为0和10之间的任意整数，条件是如果n为0，则m不等于0，如果m为0，则n不等于0；其中t独立选择自n和/或m，为0和10之间的任意整数；其中Ra、Rb、Rc、Rd和Re独立于彼此选择自包括H、烷基、环烷基、芳香族、杂芳香族和杂环烷基；Y选择自包括烷基、取代烷基、环烷基、取代环烷基、环烷烯基、取代环烷烯基、杂环烷基、取代杂环烷基、单不饱和杂环烷基、多不饱和杂环烷基、单取代多不饱和杂环烷基、多取代多不饱和杂环烷基、芳香族、取代芳香族、杂芳香族和取代杂芳香族，其中Y与肽不同。
• Phenol derivatives and their use as rotamase inhibitors
  申请人：Knolle Jochen

  公开号：US20070054904A1

  公开（公告）日：2007-03-08

  The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z 1 , Z 2 , Z 3 and Z 4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR 10 —, —C(S)—NR 11 —, —C(N—CN)—NR 12 —, —S(O)—, —S(O 2 )—, —S(O)—NR 13 —, and —S(O 2 )—NR 14 —, —O—, —S— or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y. is selected from the group comprising alkyl, substituted alkyl, straight alkyl, substituted straight alkyl, branched alkyl, substituted branched alkyl, straight alkenyl, substituted straight alkenyl, branched alkenyl, substituted branched alkenyl, straight alkynyl, substituted straight alkynyl, branched alkynyl, substituted branched alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, mono-substituted mono-unsaturated heterocyclyl, poly-substituted mono-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide or is absent.

  本发明涉及以下化合物的公式(I)、(II)、(III)、(IV)、(V)： 其中，Z1、Z2、Z3和Z4分别且独立地选自包括C(O)、-C(S)-、-C(O)-NR10-、-C(S)-NR11-、-C(N-CN)-NR12-、-S(O)-、-S(O2)-、-S(O)-NR13-和-S(O2)-NR14-、-O-、-S-的基团，或者它们各自单独不存在；X是一个间隔符，可以独立地选自-M1-L1-K-L2-M2-的基团，其中Y选自包括烷基、取代烷基、直链烷基、取代直链烷基、支链烷基、取代支链烷基、直链烯基、取代直链烯基、支链烯基、取代支链烯基、直链炔基、取代直链炔基、支链炔基、取代支链炔基、环烷基、取代环烷基、环烯基、取代环烯基、杂环基、取代杂环基、单不饱和杂环基、多不饱和杂环基、单取代多不饱和杂环基、多取代多不饱和杂环基、单取代单不饱和杂环基、多取代单不饱和杂环基、芳基、取代芳基、杂芳基和取代杂芳基，其中Y不同于肽或不存在。
• COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF
  申请人：KNOLLE Jochen

  公开号：US20110065760A1

  公开（公告）日：2011-03-17

  The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z 1 , Z 2 , Z 3 and Z 4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR 10 —, —C(S)—NR 11 —, —C(N—CN)—NR 12 —, —S(O)—, —S(O 2 )—, —S(O)—NR 13 —, and S(O 2 )—NR 14 —, —O—, —S— or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y. is selected from the group comprising alkyl, substituted alkyl, straight alkyl, substituted straight alkyl, branched alkyl, substituted branched alkyl, straight alkenyl, substituted straight alkenyl, branched alkenyl, substituted branched alkenyl, straight alkynyl, substituted straight alkynyl, branched alkynyl, substituted branched alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, mono-substituted mono-unsaturated heterocyclyl, poly-substituted mono-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide or is absent.

  本发明涉及一种式（I），（II），（III），（IV），（V）的化合物：其中Z1，Z2，Z3和Z4分别独立地选自包括C（O）—，—C（S）—，—C（O）—NR10—，—C（S）—NR11—，—C（N—CN）—NR12—，—S（O）—，—S（O2）—，—S（O）—NR13—和S（O2）—NR14—，—O—，—S—或各自缺席的基团；X是间隔基团，独立地选自包括-M1-L1-K-L2-M2-，其中Y选自包括烷基，取代烷基，直链烷基，取代直链烷基，支链烷基，取代支链烷基，直链烯基，取代直链烯基，支链烯基，取代支链烯基，直链炔基，取代直链炔基，支链炔基，取代支链炔基，环烷基，取代环烷基，环烯基，取代环烯基，杂环基，取代杂环基，单不饱和杂环基，多不饱和杂环基，单取代多不饱和杂环基，多取代多不饱和杂环基，单取代单不饱和杂环基，多取代单不饱和杂环基，芳基，取代芳基，杂芳基和取代杂芳基，其中Y不同于肽或不存在。
• New compounds for the inhibition of rotamases and use thereof
  申请人：Jerini AG

  公开号：EP2100876A2

  公开（公告）日：2009-09-16

  The present invention is related to a compound of the formula (I): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising - C(O)-, -C(S)-, -C(O)-NR10-, -C(S)-NR11-, -C(N-CN)-NR12-, -S(O)-, -S(O2)-, -S(O)-NR13-, and -S(O2)-NR14-, -O-, -S- or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y is selected from the group comprising alkyl, substituted alkyl, straight alkyl, substituted straight alkyl, branched alkyl, substituted branched alkyl, straight alkenyl, substituted straight alkenyl, branched alkenyl , substituted branched alkenyl, straight alkynyl, substituted straight alkynyl, branched alkynyl, substituted branched alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, mono-substituted mono-unsaturated heterocyclyl, poly-substituted mono-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide or is absent.

  本发明涉及一种式 (I) 的化合物： 其中 Z1、Z2、Z3 和 Z4 各自独立地选自包括 -C(O)-、-C(S)-、-C(O)-NR10-、-C(S)-NR11-、-C(N-CN)-NR12-、-S(O)-、-S(O2)-、-S(O)-NR13- 和 -S(O2)-NR14-、-O-、-S- 或各自独立地不存在的组；X 是间隔物，独立地选自包括-M1-L1-K-L2-M2-在内的组，其中 Y 选自包括烷基、取代烷基、直链烷基、取代直链烷基、支链烷基、取代支链烷基、直链烯基、取代直链烯基、支链烯基、取代支链烯基、直链炔基、取代直链炔基、支链炔基、取代支链炔基、环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、环烷基、取代环烷基、环烯基、取代环烯基、杂环烷基、取代杂环烷基、单不饱和杂环烷基、多不饱和杂环烷基、单取代多不饱和杂环烷基、多取代的多不饱和杂环基、单取代的单不饱和杂环基、多取代的单不饱和杂环基、芳基、取代的芳基、杂芳基和取代的杂芳基，其中 Y 不同于肽或不存在。